Increased mean AUC & decreased mean Cmax
w/ aspirin. Potential significant increases in Cmax
, AUC & t½
w/ propranolol. Severe hypoglycemia w/ oral miconazole. May potentiate or weaken pharmacodynamic response to warfarin. CYP2C9 inducers, inhibitors or substrates (eg, rifampicin, fluconazole, amiodarone, tolbutamide, diclofenac, ibuprofen, naproxen). Reduced or absent signs of adrenergic counter-regulation to hypoglycemia w/ sympatholytics (eg, β-blockers, clonidine, guanethidine & reserpine). Reduced absorption w/ colesevelam. May unpredictably potentiate or reduce activity w/ acute & chronic alcohol intake. May potentiate hypoglycemic action w/ NSAIDs eg, ibuprofen, phenylbutazone, oxyphenbutazone & azapropazone; clarithromycin, highly protein bound drugs, coumarins, probenecid, β-blockers, salicylates, aminosalicylic acid, anabolic steroids & male sex hormones, chloramphenicol, certain long-acting sulfonamides, tetracyclines, quinolones, fenfluramine, fibrates, ACE inhibitors, fluoxetine, MAOIs, disopyramide, allopurinol, sulfinpyrazone, cyclophosphamide, trosphosphamide, ifosfamide, miconazole, fluconazole, pentoxifylline (high-dose parenteral), tritoqualine, insulin, other oral antidiabetic drugs. Risk of hyperglycemia & loss of glycemic control w/ thiazides & other diuretics, corticosteroids, phenothiazines, chlorpromazine, thyroid products, estrogens, progestogens, nicotinic acid (high doses) & its derivatives, laxatives (long-term use), OCs, phenytoin, diazoxide, glucagons, barbiturates, rifampicin, acetazolamide, adrenaline, sympathomimetics & INH.